Lyme Diagnosis 2026: Part 2

The Next Generation of Lyme Diagnostics

When can we expect them?

For years, improving Lyme diagnostics was treated as a technical problem waiting for incremental refinement of the two-tier testing algorithm. That assumption has changed over the past decade. Today a growing number of academic laboratories and biotechnology companies are attempting something more ambitious: replace the algorithm entirely.

Several efforts are particularly worth watching.

Johns Hopkins — T-Cell Based Diagnostics

One of the most interesting diagnostic directions focuses not on antibodies, but on T-cell immune signatures. Researchers at institutions including Johns Hopkins have explored whether early Lyme infection produces distinctive cellular immune responses detectable before antibodies appear.

These approaches attempt to identify immune activation patterns rather than individual antibodies, potentially shortening the diagnostic window significantly. Early-stage studies suggest that cellular immune responses may appear days to weeks earlier than traditional serology.

The challenge, however, is regulatory validation. T-cell diagnostics are complex and have historically faced higher barriers for clinical standardization.

Adaptive Biotechnologies — TCR Sequencing Platforms

Another approach comes from companies like Adaptive Biotechnologies, which use large-scale sequencing of T-cell receptor repertoires to identify pathogen-specific immune signatures.

Their platform, previously commercialized for COVID detection, analyzes millions of T-cell receptor sequences and compares them against curated pathogen libraries.

In principle, this type of immune fingerprinting could detect Lyme infection even when antibody tests remain negative, though Lyme-specific validation work remains ongoing.

Multiplex Serology Platforms

Other groups such as Antigen Discovery Inc. are pursuing whole-proteome microarray technology to develop the above research into one stop multiplex antibody panels designed to detect multiple Borrelia antigens simultaneously rather than relying on the limited band patterns of Western blot.

Examples include assays developed through NIH-supported tick-borne disease initiatives that combine multiple recombinant antigens in a single test. Early studies suggest substantial improvements in early infection sensitivity, sometimes exceeding 90% in controlled cohorts.

Unlike T-cell tests, multiplex serology may fit more easily into existing laboratory workflows, potentially accelerating regulatory approval.

Antigen Detection and Direct Pathogen Assays

The most ambitious diagnostics attempt to detect Borrelia antigens directly, rather than host immune responses. These technologies face the hardest biological challenge: Borrelia burgdorferi circulates at extremely low levels in blood, making direct detection difficult. But improvements in microfluidics and signal amplification technologies are beginning to reopen that possibility.

T2 Biosystems’ Magnetic Resonance (T2MR) technology doesn’t just look for a signal; it amplifies it by detecting how water molecules react to the presence of the bacteria in a magnetic field. While Ceres Nanosciences is focused on “hydrogel nanoparticles” (tiny cages) that find and concentrate the Borrelia antigens from a large sample into a very small one, essentially “amplifying” the presence of the bug so a standard test can finally see it.

• Commercial Availability: Galaxy Diagnostics Nanotrap® Urine Antigen Test. Galaxy Diagnostics is the primary clinical partner offering this test to practitioners. This link provides the clinical “how-to” and the logic behind bypassing antibody testing.

If successful, these assays could eliminate the immunological delay that undermines current diagnostics.

A Different Diagnostic Strategy: Detecting the Infection Itself

One recent development illustrates the shift in diagnostic thinking has begun to yield actionable results. In early 2026, the FDA granted Breakthrough Device Designation to EC Pocket Lyme, a molecular diagnostic platform developed by En Carta Diagnostics. Rather than detecting antibodies in blood, the test is designed to detect Borrelia DNA directly from interstitial fluid at the tick bite site using a microneedle sampler. If validated in clinical trials, the approach could identify infection before the immune response that current tests rely on has even begun. The designation does not mean the test is approved, but it does place the technology on an accelerated regulatory pathway—an indication that regulators recognize the magnitude of the current diagnostic gap.

Why This Matters

The diagnostic model for Lyme disease has remained largely unchanged since the mid-1990s. The emerging generation of single-tier diagnostics represents the first credible attempt in decades to fundamentally redesign the system.

For patients navigating the diagnostic gray zone today, that shift could transform the experience from weeks of uncertainty to same-visit confirmation.

Following the Diagnostic Pipeline

The next few years may represent the most significant transition in Lyme diagnostics since the two-tier testing algorithm was adopted in the 1990s.

Multiplex serology, immune profiling, and antigen detection platforms are all moving through validation pipelines at the same time. Some will fail. A few may redefine how Lyme disease is diagnosed.

We plan to continue tracking these developments, not only the technologies themselves, but how they intersect with real-world clinical experience.

• Which tests actually shorten the diagnostic journey?
• Which approaches translate successfully from research cohorts into community practice?

Those answers will likely come not only from laboratories and regulators, but from the broader Lyme community.

If you are involved in clinical research, patient advocacy, diagnostics development, or surveillance work, we would welcome the opportunity to continue the conversation (button below).